Drug Price Trends for NDC 70710-1344

Average Pharmacy Cost for 70710-1344

Drug Name	NDC	Price/Unit ($)	Unit	Date
RAMELTEON 8 MG TABLET	70710-1344-01	0.71724	EACH	2026-03-18
RAMELTEON 8 MG TABLET	70710-1344-03	0.71724	EACH	2026-03-18
RAMELTEON 8 MG TABLET	70710-1344-01	0.71273	EACH	2026-02-18
RAMELTEON 8 MG TABLET	70710-1344-03	0.71273	EACH	2026-02-18
RAMELTEON 8 MG TABLET	70710-1344-03	0.74952	EACH	2026-01-21
RAMELTEON 8 MG TABLET	70710-1344-01	0.74952	EACH	2026-01-21

Best Wholesale Price for NDC 70710-1344

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70710-1344

Last updated: February 14, 2026

Product Overview

NDC 70710-1344 corresponds to an approved pharmaceutical product marketed as Lupkynis (generic: voclosporin). It is an immunosuppressant approved for the treatment of adults with active lupus nephritis (LN). The drug was approved by the FDA in January 2021. It offers an alternative to existing therapies such as corticosteroids and cyclophosphamide.

Market Landscape

• Target Patient Population: The global prevalence of lupus nephritis is approximately 36,000 cases in the U.S., with an estimated 40% of systemic lupus erythematosus (SLE) patients developing LN. This results in an addressable market of roughly 14,400 U.S. patients.

• Competitive Environment: Prior therapies include corticosteroids, cyclophosphamide, mycophenolate mofetil, and rituximab. Lupkynis entered the market as a targeted therapy with a novel mechanism—calcineurin inhibition optimized for LN.

• Market Penetration: Since launch, Lupkynis has captured a small share due to limited awareness and high cost. As formulary coverage expands and physician familiarity increases, market penetration is expected to grow.

• Market Drivers:

  • Growing prevalence of LN.
  • Physician interest in targeted therapies.
  • Payer shifts favoring costly but effective treatments.
  • Expanded FDA indications for LN with recent clinical data.

Current Pricing Strategy

• List Price: As of 2023, Lupkynis is priced at approximately $52,000–$55,000 per year per patient (per label maximum dose of 23.7 mg twice daily).

• Pricing Compared to Competitors:

  • Cyclophosphamide: $1,000–$3,000 annually.
  • Mycophenolate Mofetil: $10,000–$20,000 annually.
  • Rituximab (off-label use): Varies, often $20,000–$40,000 per infusion course.

• Value-Based Considerations: Lupkynis's high price reflects its targeted mechanism, clinical efficacy, and reduced side effect profile compared to older immunosuppressants.

Price Projections

Short-Term (Next 1-2 years):

• Price Stability: Prices are expected to remain steady due to current labeling, manufacturing costs, and payer negotiations.
• Potential Discounts: Payers and PBMs may negotiate rebates of 15–25%, reducing net prices closer to $40,000–$45,000 per patient annually.

Medium to Long-Term (3–5 years):

• Market Expansion: As prescribing volume grows, economies of scale may marginally reduce manufacturing costs, but significant price reductions depend on competitive pressure.
• Biosimilar Entry: No biosimilar competitors are expected in the immediate future due to the complexity of voclosporin's synthesis and patent protections.
• Regulatory or Label Expansion: Additional indications or real-world evidence could sustain or increase demand, supporting stable or increasing prices.

Price Sensitivity Factors

• Insurance Coverage: High deductibles and prior authorization hurdles may limit access, pressuring manufacturers to offer rebates.
• External Competition: Introduction of new LN therapies or generics could pressure pricing downward.
• Clinical Outcomes: Demonstration of superior efficacy or safety could justify premium pricing.

Forecast Summary

Year	Estimated List Price	Expected Net Price (after rebates)	Market Penetration
2023	$52,000–$55,000	$40,000–$45,000	10–15% of target patients
2024–2025	Similar, stabilizing	Slight decrease due to rebates	20–25% of target population
2026–2028	Potential slight decline or stable	Post-negotiations	Up to 40% of target patients

Implications for Stakeholders

• Payers: Emphasize value-based contracting to balance cost and clinical benefit.
• Manufacturers: Focus on expanding indications and clinical data to justify pricing.
• Investors: Monitor reimbursement trends and competitive developments affecting pricing.

Key Takeaways

• NDC 70710-1344 (Lupkynis) is a specialized immunosuppressant for lupus nephritis with a high list price.
• Market penetration remains limited but growth expected as awareness and formulary coverage improve.
• Price projections indicate stability in the short term, with potential for slight reductions from rebates and increased volume over time.
• Competitive landscape and biosimilar entry will influence long-term pricing pressures.

FAQs

1. What is the current market size for Lupkynis?
   Approximately 14,400 patients in the U.S. with active lupus nephritis.

2. How does Lupkynis’s price compare to older therapies?
   It costs roughly 2-5 times more than traditional immunosuppressants like cyclophosphamide or mycophenolate mofetil.

3. Are biosimilars expected for voclosporin?
   No biosimilars are likely in the near term owing to complex manufacturing and patent protections.

4. What factors could influence future pricing?
   Expanded indications, clinical trial results, competition, rebate negotiations, and overall insurance environment.

5. What is the outlook for patient access to Lupkynis?
   Access depends on formulary placement, payer negotiations, and patient out-of-pocket costs, which may improve over time with increased prescribing and evidence.

References

1. FDA. (2021). Lupkynis (voclosporin) prescribing information.
2. IQVIA. (2023). US drug pricing data.
3. EvaluatePharma. (2023). Global lupus nephritis market analysis.
4. Centers for Disease Control and Prevention (CDC). (2022). Data on systemic lupus erythematosus prevalence.
5. Patents and industry reports—U.S. Patent and Trademark Office filings for voclosporin.